Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intraflagellar transport protein 56 (IFT56, also known as TTC26 or DYF13) is a protein component of the intraflagellar transport (IFT) complex B, which is essential for the assembly, maintenance, and function of cilia and flagella in eukaryotic cells[2]. IFT56 mediates the transport of specific cargo proteins related to ciliary and flagellar motility, particularly the inner dynein arms and other regulatory complexes, ensuring proper ciliary beat and length. Loss or mutation of IFT56 leads to shortened and dysfunctional cilia and flagella, causing diverse developmental and organ defects, as demonstrated in zebrafish, mice, and algae models[2]. IFT56 is believed to act as an adaptor within the IFT-B complex and is a peripheral, but not core, IFT-B component. There is currently no evidence that IFT56 is a direct therapeutic target or that drugs have been developed to modulate its function. Its primary importance is in research on ciliary biology and diseases resulting from ciliary dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intraflagellar transport protein 56 (IFT56).